Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.38 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | POLQ | O75417 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2407265 | 0.96 | IDO1 (0.53) | IDO1POLQMAOBGRIN2BGRIN1 | |
| SCHEMBL1395805 | 0.79 | POLQ (0.55) | IDO1POLQMAOBGRIN2BGRIN1 | |
| SCHEMBL27770731 | 0.79 | IDO1 (0.52) | IDO1POLQMAOBGRIN2BGRIN1 | |
| SCHEMBL11104251 | 0.79 | PKM (0.53) | IDO1POLQMAOBGRIN2BGRIN1 | |
| Hydrochloric Acid SCHEMBL8413702 | 0.78 | POLQ (0.54) | IDO1POLQMAOBGRIN2BGRIN1 | |
| SCHEMBL21729165 | 0.78 | LMNA (0.53) | IDO1POLQMAOBGRIN2BGRIN1 | |
| Bromide SCHEMBL17260892 | 0.77 | IDO1 (0.56) | IDO1ALDH1A1 | |
| SCHEMBL2968062 | 0.76 | IDO1 (0.55) | IDO1POLQMAOBGRIN2BGRIN1 | |
| SCHEMBL6714080 | 0.76 | POLQ (0.55) | IDO1POLQMAOBALDH1A1POLB | |
| SCHEMBL11104249 | 0.76 | POLQ (0.47) | IDO1POLQMAOBALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2539326-B1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-25 | — | — | US | disclosed |
| US-9187466-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| CN-103189363-B | Biaryl linked aryl triazolones and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-29 | — | — | CN | disclosed |
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| CN-103189363-A | Biaryl linked aryl triazolones and uses thereof | BAYER IP GMBH | 2013-07-03 | — | — | CN | disclosed |
| EP-2539326-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190330-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | GRIN2A 2920/4885SIGMAR1 3466/4885IDO1 998/4885 |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | GRIN2A 2920/4885SIGMAR1 3466/4885IDO1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.